Marigold J H, Morgan A K, Earle D J, Young A E, Croft D N
Br J Surg. 1985 Jan;72(1):45-7. doi: 10.1002/bjs.1800720118.
It has been established practice for 60 years to prepare thyrotoxic patients undergoing thyroidectomy with Lugol's iodine. However, evidence in support of its claimed benefits, namely a reduction in the vascularity and friability of the toxic thyroid gland, is scanty. We have therefore determined the effect of Lugol's iodine on thyroid blood flow, as measured by thyroid uptake of thallium-201, in nine patients with Graves' disease and one euthyroid patient. Thallium-201 uptake, as well as serum thyroxine and triiodothyronine, fell significantly after treatment with iodine. Although not correlated with thyroid function tests, thallium-201 uptake was significantly correlated with thyroid weight. These results support the contention that thyroid blood flow is reduced in thyrotoxic patients treated with Lugol's iodine.
用卢戈氏碘剂为接受甲状腺切除术的甲状腺毒症患者做术前准备已有60年的既定做法。然而,支持其声称益处(即减少毒性甲状腺的血管分布和脆性)的证据却很少。因此,我们测定了卢戈氏碘剂对9例格雷夫斯病患者和1例甲状腺功能正常患者甲状腺血流的影响,甲状腺血流通过甲状腺对铊-201的摄取来测量。碘治疗后,铊-201摄取以及血清甲状腺素和三碘甲状腺原氨酸均显著下降。虽然铊-201摄取与甲状腺功能检查无关,但与甲状腺重量显著相关。这些结果支持了用卢戈氏碘剂治疗的甲状腺毒症患者甲状腺血流减少的观点。